JPWO2020172093A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020172093A5 JPWO2020172093A5 JP2021548153A JP2021548153A JPWO2020172093A5 JP WO2020172093 A5 JPWO2020172093 A5 JP WO2020172093A5 JP 2021548153 A JP2021548153 A JP 2021548153A JP 2021548153 A JP2021548153 A JP 2021548153A JP WO2020172093 A5 JPWO2020172093 A5 JP WO2020172093A5
- Authority
- JP
- Japan
- Prior art keywords
- unsubstituted
- substituted
- alkyl
- cycloalkyl
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical group [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 38
- 125000000217 alkyl group Chemical group 0.000 claims 30
- 150000001875 compounds Chemical class 0.000 claims 26
- 229910052739 hydrogen Inorganic materials 0.000 claims 25
- 239000001257 hydrogen Substances 0.000 claims 25
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 24
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 24
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 24
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 23
- 229910052736 halogen Inorganic materials 0.000 claims 18
- 150000002367 halogens Chemical class 0.000 claims 18
- 125000003118 aryl group Chemical group 0.000 claims 13
- 125000001072 heteroaryl group Chemical group 0.000 claims 13
- 125000004093 cyano group Chemical group *C#N 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 10
- 125000004043 oxo group Chemical group O=* 0.000 claims 9
- 229940124597 therapeutic agent Drugs 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 4
- 102100030013 Endoribonuclease Human genes 0.000 claims 3
- 101001010783 Homo sapiens Endoribonuclease Proteins 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 3
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- 125000006568 (C4-C7) heterocycloalkyl group Chemical group 0.000 claims 1
- -1 6 -substituted cyclohexyl Chemical group 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 206010061424 Anal cancer Diseases 0.000 claims 1
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 1
- 102000007072 Nerve Growth Factors Human genes 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000002471 Penile Neoplasms Diseases 0.000 claims 1
- 206010034299 Penile cancer Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 claims 1
- 206010061934 Salivary gland cancer Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 206010047741 Vulval cancer Diseases 0.000 claims 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 201000011165 anus cancer Diseases 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003623 enhancer Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 208000014951 hematologic disease Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 239000003900 neurotrophic factor Substances 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000002628 peritoneum cancer Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 201000005102 vulva cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019075328 | 2019-02-18 | ||
| CNPCT/CN2019/075328 | 2019-02-18 | ||
| PCT/US2020/018499 WO2020172093A1 (en) | 2019-02-18 | 2020-02-17 | Pyrido-pyrimidinyl compounds and methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022521724A JP2022521724A (ja) | 2022-04-12 |
| JPWO2020172093A5 true JPWO2020172093A5 (enExample) | 2023-02-22 |
| JP7611154B2 JP7611154B2 (ja) | 2025-01-09 |
Family
ID=69811949
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021548153A Active JP7611154B2 (ja) | 2019-02-18 | 2020-02-17 | ピリド－ピリミジニル化合物及び使用の方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220204498A1 (enExample) |
| EP (1) | EP3927433A1 (enExample) |
| JP (1) | JP7611154B2 (enExample) |
| CN (1) | CN113795307A (enExample) |
| AR (1) | AR118119A1 (enExample) |
| TW (1) | TWI756636B (enExample) |
| WO (1) | WO2020172093A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102396930B1 (ko) * | 2020-01-15 | 2022-05-12 | 한국과학기술연구원 | 피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물 |
| JP2023528659A (ja) | 2020-06-08 | 2023-07-05 | ハリア・セラピューティクス・インコーポレイテッド | Ｎｅｋ７キナーゼの阻害剤 |
| US12577240B2 (en) | 2020-07-11 | 2026-03-17 | Pfizer Inc. | Antiviral heteroaryl ketone derivatives |
| US11351149B2 (en) | 2020-09-03 | 2022-06-07 | Pfizer Inc. | Nitrile-containing antiviral compounds |
| CN116710429A (zh) * | 2020-11-13 | 2023-09-05 | 加利福尼亚大学董事会 | IRE1α抑制剂及其用途 |
| JP2023549540A (ja) | 2020-11-18 | 2023-11-27 | デシフェラ・ファーマシューティカルズ，エルエルシー | Ｇｃｎ２およびｐｅｒｋキナーゼ阻害剤およびその使用方法 |
| JP2024544632A (ja) | 2021-12-03 | 2024-12-03 | デシフェラ・ファーマシューティカルズ，エルエルシー | Ｇｃｎ２及びｐｅｒｋキナーゼ阻害剤としての複素環式化合物 |
| WO2024131893A1 (en) * | 2022-12-22 | 2024-06-27 | Shanghai Yi Zhong Xing Biotechnology Co., Ltd. | IRE1α SMALL MOLECULE INHIBITORS |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| MXPA06012613A (es) | 2004-05-07 | 2007-01-31 | Amgen Inc | Derivados heterociclicos nitrogenados como moduladores de proteina cinasa y uso para el tratamiento de angiogenesis y cancer. |
| US20070054916A1 (en) * | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| US7868177B2 (en) | 2006-02-24 | 2011-01-11 | Amgen Inc. | Multi-cyclic compounds and method of use |
| US8338435B2 (en) * | 2006-07-20 | 2012-12-25 | Gilead Sciences, Inc. | Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections |
| CA2737388C (en) | 2008-09-15 | 2017-07-11 | Peter Walter | Methods and compositions for modulating ire1, src, and abl activity |
| WO2013090840A1 (en) * | 2011-12-15 | 2013-06-20 | Gilead Sciences, Inc. | 2 -amino- pyrido [3, 2 -d] pyrimidine derivatives as hcv inhibitors |
| AR090151A1 (es) * | 2012-03-07 | 2014-10-22 | Lilly Co Eli | Compuestos inhibidores de raf |
| EP3548476A4 (en) * | 2016-12-02 | 2020-05-20 | Quentis Therapeutics, Inc. | SMALL MOLECULAR IRE1 INHIBITORS |
| AU2018278311B2 (en) * | 2017-06-01 | 2021-10-07 | Cornell University | IRE1 small molecule inhibitors |
| AU2019393754A1 (en) * | 2018-12-03 | 2021-07-22 | Cornell University | IRE1 small molecule inhibitors |
| TWI748317B (zh) * | 2019-01-03 | 2021-12-01 | 美商建南德克公司 | 吡啶并－嘧啶酮與喋啶酮化合物及使用方法 |
| EP3962484A4 (en) * | 2019-05-03 | 2023-01-18 | Kinnate Biopharma Inc. | RAF KINASE INHIBITORS |
| KR102396930B1 (ko) * | 2020-01-15 | 2022-05-12 | 한국과학기술연구원 | 피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물 |
-
2020
- 2020-02-17 WO PCT/US2020/018499 patent/WO2020172093A1/en not_active Ceased
- 2020-02-17 CN CN202080014852.XA patent/CN113795307A/zh active Pending
- 2020-02-17 AR ARP200100431A patent/AR118119A1/es unknown
- 2020-02-17 EP EP20711446.3A patent/EP3927433A1/en active Pending
- 2020-02-17 JP JP2021548153A patent/JP7611154B2/ja active Active
- 2020-02-17 TW TW109104995A patent/TWI756636B/zh active
-
2021
- 2021-08-17 US US17/404,568 patent/US20220204498A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102166002B1 (ko) | 섬유 아세포 성장 인자 수용체 키나아제 억제제인 인다졸계 화합물 및 이의 제조와 응용 | |
| JPWO2019212990A5 (enExample) | ||
| JP2014193925A5 (enExample) | ||
| JP2015506347A5 (enExample) | ||
| JPWO2019191470A5 (enExample) | ||
| JP2005320351A5 (enExample) | ||
| JP2016523973A5 (enExample) | ||
| WO2023036285A1 (zh) | 一种杂芳环类化合物及其应用 | |
| JP2006505623A5 (enExample) | ||
| JPWO2020172093A5 (enExample) | ||
| WO2025077770A1 (zh) | 一种稠环化合物及在kras抑制剂方面的应用 | |
| JP2007515419A5 (enExample) | ||
| CN105622709A (zh) | 丹参酮i衍生物及其制备方法和应用 | |
| JP2022539126A (ja) | ベンゾジアゼピン系化合物及びその製造方法並びに医薬における作用 | |
| JP2010515693A5 (enExample) | ||
| WO2022089225A1 (zh) | 氘代hpk1激酶抑制剂及其制备方法和应用 | |
| CN108658962A (zh) | 3-取代香豆素呋咱衍生物及其在制备抗多药耐药肿瘤药物中的用途 | |
| WO2013107428A1 (zh) | 7-位取代的汉防己乙素衍生物、及其制备方法和应用 | |
| JP2019522681A5 (enExample) | ||
| CN112243437B (zh) | 含丙烯酰基的核转运调节剂及其用途 | |
| CN110437119B (zh) | 一种n-取代含氮杂环衍生物及其制备方法与应用 | |
| JP2019526593A5 (enExample) | ||
| US20090005406A1 (en) | Cancer Treatment Method | |
| WO2023078369A1 (zh) | 双环化合物及其应用 | |
| CN112778217B (zh) | 一种喹唑啉类化合物及其应用 |